DAFTAR PUSTAKA

Abarca, Romina L. *et al*. 2016. “Characterization of Beta-Cyclodextrin Inclusion Complexes Containing an Essential Oil Component.” *Food Chemistry* 196: 968–75. http://dx.doi.org/10.1016/j.foodchem.2015.10.023.

Al-japairai, Khater Ahmed Saeed *et al*. 2020. “Since January 2020 Elsevier Has Created a COVID-19 Resource Centre with Free Information in English and Mandarin on the Novel Coronavirus COVID- 19 . The COVID-19 Resource Centre Is Hosted on Elsevier Connect , the Company ’ s Public News and Information .” (January).

Ananda, Putri Wulandari Resky *et al*. 2021. “Combination of Transdermal Patches and Solid Microneedles for Improved Transdermal Delivery of Primaquine.” *International Journal of Pharmaceutics* 609(August): 121204. https://doi.org/10.1016/j.ijpharm.2021.121204.

Anjani, Qonita Kurnia *et al*. 2022. “Inclusion Complexes of Rifampicin with Native and Derivatized Cyclodextrins: In Silico Modeling, Formulation, and Characterization.” *Pharmaceuticals* 15(1).

Arfiputri, Dharin Serebrina, Afif Nurul Hidayati, Samsriyaningsih Handayani, and Evy Ervianti. 2018. “Risk Factors of Vulvovaginal Candidiasis in Dermato-Venereology Outpatients Clinic of Soetomo General Hospital, Surabaya, Indonesia.” *African Journal of Infectious Diseases* 12(Special Issue 1): 90–94.

Astuti, Ratnaningsih Dewi, and Siti Khotimah. 2021. “ Patch Formulation of Celery Leaves Extract (Apium Graveolens L.) As Mosquito Repellent .” *Proceedings of the First International Conference on Health, Social Sciences and Technology (ICoHSST 2020)* 521(ICoHSST 2020): 83–87.

Calvo, Natalia L. *et al*. 2019. 556 International Journal of Pharmaceutics *Chitosan-Hydroxypropyl Methylcellulose Tioconazole Films: A Promising Alternative Dosage Form for the Treatment of Vaginal Candidiasis*. Elsevier B.V. https://doi.org/10.1016/j.ijpharm.2018.12.011.

Carneiro, Simone Braga *et al*. 2019. “Cyclodextrin-Drug Inclusion Complexes: In Vivo and in Vitro Approaches.” *International Journal of Molecular Sciences* 20(3): 1–23.

Charumanee, Suporn *et al*. 2016. “Effect of Cyclodextrin Types and Co-Solvent on Solubility of a Poorly Water Soluble Drug.” *Scientia Pharmaceutica* 84(4): 694–704.

Chin, Willy *et al*. 2018. “A Macromolecular Approach to Eradicate Multidrug Resistant Bacterial Infections While Mitigating Drug Resistance Onset.”

Nature Communications 9(1): 1–14. http://dx.doi.org/10.1038/s41467-018-03325-6.

Cid-Samamed, Antonio *et al*. 2022. “Cyclodextrins Inclusion Complex: Preparation Methods, Analytical Techniques and Food Industry Applications.” *Food Chemistry* 384(August 2021): 132467. https://doi.org/10.1016/j.foodchem.2022.132467.

Dardeer, Hemat Mohamed. 2014. “Importance of Cyclodextrins into Inclusion Complexes.” *International Journal of Advanced Research Journalwww.journalijar.com INTERNATIONAL JOURNAL OF ADVANCED RESEARCH* 2(4): 414–28.

Ben David, Noa *et al*. 2023. “Design and Evaluation of Dissolvable Microneedles for Treating Atopic Dermatitis.” *Pharmaceutics* 15(4).

Dorgan, Eileen, David W. Denning, and Ronan McMullan. 2015. “Burden of Fungal Disease in Ireland.” *Journal of Medical Microbiology* 64(4): 423–26.

Duchene, Dominique. 2011. “Part i Cyclodextrins: History, Properties, Applications, and Current Status.” *Cyclodextrin: History, Properties, Applications, and Current Status*: 3–18.

Fairuz, Shadreen, Rajesh Sreedharan Nair, and Nashiru Billa. 2022. “Orally Administered Amphotericin B Nanoformulations: Physical Properties of Nanoparticle Carriers on Bioavailability and Clinical Relevance.” *Pharmaceutics* 14(9).

Fernández-García, Raquel, Esther de Pablo, María Paloma Ballesteros, and Dolores R. Serrano. 2017. “Unmet Clinical Needs in the Treatment of Systemic Fungal Infections: The Role of Amphotericin B and Drug Targeting.” *International Journal of Pharmaceutics* 525(1): 139–48. http://dx.doi.org/10.1016/j.ijpharm.2017.04.013.

Fischer, Gayle. 2012. “Chronic Vulvovaginal Candidiasis: What We Know and What We Have yet to Learn.” *Australasian Journal of Dermatology* 53(4): 247–54.

Gagoś, Mariusz, and Marta Arczewska. 2010. “Spectroscopic Studies of Molecular Organization of Antibiotic Amphotericin B in Monolayers and Dipalmitoylphosphatidylcholine Lipid Multibilayers.” *Biochimica et Biophysica Acta - Biomembranes* 1798(11): 2124–30.

Gannimani, Ramesh *et al*. 2015. “Antipyrine-Gamma Cyclodextrin Inclusion Complex: Molecular Modeling, Preparation, Characterization and Cytotoxicity Studies.” *Journal of Molecular Structure* 1089: 38–47. http://dx.doi.org/10.1016/j.molstruc.2015.02.017.

Ghosh, A., S. Biswas, and T. Ghosh. 2011. “Preparation and Evaluation of Silymarin β-Cyclodextrin Molecular Inclusion Complexes.” *Journal of*

Young Pharmacists 3(3): 205–10.

González-Vázquez, Patricia *et al*. 2017a. “Transdermal Delivery of Gentamicin Using Dissolving Microneedle Arrays for Potential Treatment of Neonatal Sepsis.” *Journal of Controlled Release* 265: 30–40. http://dx.doi.org/10.1016/j.jconrel.2017.07.032.

———. 2017b. “Transdermal Delivery of Gentamicin Using Dissolving Microneedle Arrays for Potential Treatment of Neonatal Sepsis.” *Journal of Controlled Release* 265(August): 30–40. http://dx.doi.org/10.1016/j.jconrel.2017.07.032.

GÖRGÜLÜ, Güvenç, and Bülent DEDE. 2023. “Comparison of The Molecular Docking Properties of Three Potentially Active Agents.” *International Journal of Computational and Experimental Science and Engineering* 9(2): 81–85.

Haimhoffer, Ádám *et al*. 2019. “Cyclodextrins in Drug Delivery Systems and Their Effects on Biological Barriers.” *Scientia Pharmaceutica* 87(4): 1–20.

Hong, Xiaoyun *et al*. 2014. “Hydrogel Microneedle Arrays for Transdermal Drug Delivery.” *Nano-Micro Letters* 6(3): 191–99.

Jamaledin, Rezvan *et al*. 2020. “Advances in Antimicrobial Microneedle Patches for Combating Infections.” *Advanced Materials* 32(33): 1–29.

Jansook, Phatsawee, Zoltán Fülöp, and Garnpimol C. Ritthidej. 2019. “Amphotericin B Loaded Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carrier (NLCs): Physicochemical and Solid-Solution State Characterizations.” *Drug Development and Industrial Pharmacy* 45(4): 560–67. http://dx.doi.org/10.1080/03639045.2019.1569023.

Johal, Himmat Singh, Tarun Garg, Goutam Rath, and Amit Kumar Goyal. 2016. “Advanced Topical Drug Delivery System for the Management of Vaginal Candidiasis.” *Drug Delivery* 23(2): 550–63.

Juster-Reicher, Ada *et al*. 2000. “Liposomal Amphotericin B (AmBisome) in the Treatment of Neonatal Candidiasis in Very Low Birth Weight Infants.” *Infection* 28(4): 223–26.

Kamaruzzaman, Nor Fadhilah *et al*. 2019. “Antimicrobial Polymers: The Potential Replacement of Existing Antibiotics?” *International Journal of Molecular Sciences* 20(11).

Kim, Si Hyun *et al*. 2016. “Therapeutic Drug Monitoring and Safety of Intravenous Voriconazole Formulated with Sulfobutylether β-Cyclodextrin in Haematological Patients with Renal Impairment.” *Mycoses* 59(10): 644–51.

Kim, Ye Tae *et al*. 2010. “A Thermosensitive Vaginal Gel Formulation with

HPγCD for the PH-Dependent Release and Solubilization of Amphotericin B." *European Journal of Pharmaceutical Sciences* 41(2): 399–406. http://dx.doi.org/10.1016/j.ejps.2010.07.009.

Kristina Enggi, Cindy *et al*. 2023. "Development of Probiotic Loaded Multilayer Microcapsules Incorporated into Dissolving Microneedles for Potential Improvement Treatment of Vulvovaginal Candidiasis: A Proof of Concept Study." *Journal of Colloid and Interface Science* 648(June): 203–19. https://doi.org/10.1016/j.jcis.2023.05.165.

Larrañeta, Eneko *et al*. 2014. "A Proposed Model Membrane and Test Method for Microneedle Insertion Studies." *International Journal of Pharmaceutics* 472(1–2): 65–73. http://dx.doi.org/10.1016/j.ijpharm.2014.05.042.

Li, Yu *et al*. 2020. "Preparation of Microcapsules Coating and the Study of Their Bionic Anti-Fouling Performance." *Materials* 13(7).

Lilleby Helberg, Ragne Marie, Zhongde Dai, Luca Ansaloni, and Liyuan Deng. 2020. "PVA/PVP Blend Polymer Matrix for Hosting Carriers in Facilitated Transport Membranes: Synergistic Enhancement of CO2 Separation Performance." *Green Energy and Environment* 5(1): 59–68. https://doi.org/10.1016/j.gee.2019.10.001.

Liu, Hao Yang, Lei Du, Yan Teng Zhao, and Wei Qun Tian. 2015. "In Vitro Hemocompatibility and Cytotoxicity Evaluation of Halloysite Nanotubes for Biomedical Application." *Journal of Nanomaterials* 2015.

Loh, Gabriel Onn Kit, Yvonne Tze Fung Tan, and Kok Khiang Peh. 2016. "Enhancement of Norfloxacin Solubility via Inclusion Complexation with β-Cyclodextrin and Its Derivative Hydroxypropyl-β-Cyclodextrin." *Asian Journal of Pharmaceutical Sciences* 11(4): 536–46. http://dx.doi.org/10.1016/j.ajps.2016.02.009.

López-Castillo, Carmen, Carmina Rodríguez-Fernández, Manuel Córdoba, and Juan J. Torrado. 2018. "Permeability Characteristics of a New Antifungal Topical Amphotericin B Formulation with γ-Cyclodextrins." *Molecules* 23(12).

Mader, William J., and Takeru Higuchi. 1970. "Phase Solubility Analysis." *C R C Critical Reviews in Analytical Chemistry* 1(2): 193–215.

Madera-Santana, T. J., Y. Freile-Pelegrín, and J. A. Azamar-Barrios. 2014. "Physicochemical and Morphological Properties of Plasticized Poly(Vinyl Alcohol)-Agar Biodegradable Films." *International Journal of Biological Macromolecules* 69: 176–84. http://dx.doi.org/10.1016/j.ijbiomac.2014.05.044.

"Mathematical Models of Drug Release." 2015. *Strategies to Modify the Drug Release from Pharmaceutical Systems*: 63–86.

Melo, Carolina Mirtes *et al*. 2020. “Amphotericin B-Loaded Eudragit RL100 Nanoparticles Coated with Hyaluronic Acid for the Treatment of Vulvovaginal Candidiasis.” *Carbohydrate Polymers* 230(October): 115608. https://doi.org/10.1016/j.carbpol.2019.115608.

Mesdaghinia, Alireza *et al*. 2019. “An in Vitro Method to Evaluate Hemolysis of Human Red Blood Cells (RBCs) Treated by Airborne Particulate Matter (PM 10).” *MethodsX* 6: 156–61.

Mobasheri, Meysam *et al*. 2016. “Solubilization Behavior of Polyene Antibiotics in Nanomicellar System: Insights from Molecular Dynamics Simulation of the Amphotericin B and Nystatin Interactions with Polysorbate 80.” *Molecules* 21(1).

Mudjahid, Mukarram *et al*. 2022. “Enhancement in Site-Specific Delivery of Chloramphenicol Using Bacterially Sensitive Microparticle Loaded into Dissolving Microneedle: Potential for Enhanced Effectiveness Treatment of Cellulitis.” *ACS Applied Materials and Interfaces*.

Munnangi, Siva Ram *et al*. 2023. “Drug Complexes: Perspective from Academic Research and Pharmaceutical Market.” *Pharmaceutical Research* 40(6): 1519–40. https://doi.org/10.1007/s11095-023-03517-w.

Octavia, Maria Dona *et al*. 2015. “Journal of Chemical and Pharmaceutical Research , 2015 , 7 (2): 740-747 Research Article Preparation of Simvastatin- β - Cyclodextrin Inclusion Complexes Using Co-Evaporation Technique.” 7(2): 740–47.

Peng, Ke *et al*. 2021. “Dissolving Microneedle Patches Loaded with Amphotericin B Microparticles for Localised and Sustained Intradermal Delivery: Potential for Enhanced Treatment of Cutaneous Fungal Infections.” *Journal of Controlled Release* 339(September): 361–80.

Permana, Andi Dian *et al*. 2019. “Solid Lipid Nanoparticle-Based Dissolving Microneedles: A Promising Intradermal Lymph Targeting Drug Delivery System with Potential for Enhanced Treatment of Lymphatic Filariasis.” *Journal of Controlled Release* 316(September): 34–52.

———. 2020. “Dissolving Microneedle-Mediated Dermal Delivery of Itraconazole Nanocrystals for Improved Treatment of Cutaneous Candidiasis.” *European Journal of Pharmaceutics and Biopharmaceutics* 154(April): 50–61. https://doi.org/10.1016/j.ejpb.2020.06.025.

Rawson, T. M. *et al*. 2018. “Delivering Precision Antimicrobial Therapy through Closed-Loop Control Systems.” *Journal of Antimicrobial Chemotherapy* 73(4): 835–43.

Roy, Girdhari *et al*. 2019. 572 International Journal of Pharmaceutics *Amphotericin B Containing Microneedle Ocular Patch for Effective*

Treatment of Fungal Keratitis. Elsevier B.V. https://doi.org/10.1016/j.ijpharm.2019.118808.

Sabri, Akmal H. *et al*. 2019. “Expanding the Applications of Microneedles in Dermatology.” *European Journal of Pharmaceutics and Biopharmaceutics* 140(January): 121–40. https://doi.org/10.1016/j.ejpb.2019.05.001.

Sanz, Roser *et al*. 2018. “Development of a Mucoadhesive Delivery System for Control Release of Doxepin with Application in Vaginal Pain Relief Associated with Gynecological Surgery.” *International Journal of Pharmaceutics* 535(1–2): 393–401. http://dx.doi.org/10.1016/j.ijpharm.2017.11.027.

Saokham, Phennapha, Chutimon Muankaew, Phatsawee Jansook, and Thorsteinn Loftsson. 2018. “Solubility of Cyclodextrins and Drug/Cyclodextrin Complexes.” *Molecules* 23(5): 1–15.

Sci, Food. 2020. “Department of Food and Nutrition, Kyungnam University, Gyeongnam 51767, Korea.” *Preventive Nutrition and Food Science* 25(4): 440–48.

Shankar, Nayak Bhabani, Rout Prasant Kumar, Nayak Udaya Kumar, and Bhowmik Benoy Brata. 2010. “Development and Characterization of Bioadhesive Gel of Microencapsulated Metronidazole for Vaginal Use.” *Iranian Journal of Pharmaceutical Research* 9(3): 209–19.

Shim, Woo Sun *et al*. 2018. “Role of Polyvinylpyrrolidone in Dissolving Microneedle for Efficient Transdermal Drug Delivery: In Vitro and Clinical Studies.” *Bulletin of the Korean Chemical Society* 39(6): 789–93.

Sobel, Jack D. 2016. “Recurrent Vulvovaginal Candidiasis.” *American Journal of Obstetrics and Gynecology* 214(1): 15–21. http://dx.doi.org/10.1016/j.ajog.2015.06.067.

Sosa, Lilian *et al*. 2019. “Thermoreversible Gel-Loaded Amphotericin B for the Treatment of Dermal and Vaginal Candidiasis.” *Pharmaceutics* 11(7): 1–18.

Sun, Xiaowen *et al*. 2022. “Fabrication of Fucoxanthin/2-Hydroxypropyl-β-Cyclodextrin Inclusion Complex Assisted by Ultrasound Procedure to Enhance Aqueous Solubility, Stability and Antitumor Effect of Fucoxanthin.” *Ultrasonics Sonochemistry* 90(September): 106215. https://doi.org/10.1016/j.ultsonch.2022.106215.

Wang, Qi Lei *et al*. 2016. “Microneedles with Controlled Bubble Sizes and Drug Distributions for Efficient Transdermal Drug Delivery.” *Scientific Reports* 6(June): 1–11.

———. 2018. “Effect of Humidity on Mechanical Properties of Dissolving

Microneedles for Transdermal Drug Delivery." *Journal of Industrial and Engineering Chemistry* 59: 251–58. http://dx.doi.org/10.1016/j.jiec.2017.10.030.

Yan, Qinying *et al*. 2020. "Dissolving Microneedles for Transdermal Delivery of Huperzine A for the Treatment of Alzheimer ' s Disease Treatment of Alzheimer ' s Disease." *Drug Delivery* 27(1): 1147–55. https://doi.org/10.1080/10717544.2020.1797240.

Yang, Zhi Gang, Hong Xiang Sun, and Wei Huan Fang. 2005. "Haemolytic Activities and Adjuvant Effect of Astragalus Membranaceus Saponins (AMS) on the Immune Responses to Ovalbumin in Mice." *Vaccine* 23(44): 5196–5203.

Yano, Junko *et al*. 2019. "Current Patient Perspectives of Vulvovaginal Candidiasis : Incidence , Symptoms , Management and Post-Treatment Outcomes." : 1–9.

Zafar, Ameeduzzafar *et al*. 2021. "Formulation of Genistein-Hp β Cyclodextrin-Poloxamer 188 Ternary Inclusion Complex: Solubility to Cytotoxicity Assessment." *Pharmaceutics* 13(12).

Zhou, Hui Yun, Yan Ping Zhang, Wei Fen Zhang, and Xi Guang Chen. 2011. "Biocompatibility and Characteristics of Injectable Chitosan-Based Thermosensitive Hydrogel for Drug Delivery." *Carbohydrate Polymers* 83(4): 1643–51. http://dx.doi.org/10.1016/j.carbpol.2010.10.022.

Zu, Yuangang *et al*. 2014. "Preparation and Characterization of Amorphous Amphotericin B Nanoparticles for Oral Administration through Liquid Antisolvent Precipitation." *European Journal of Pharmaceutical Sciences* 53(1): 109–17. http://dx.doi.org/10.1016/j.ejps.2013.12.005.

LAMPIRAN

Lampiran 1. Skema Kerja Penelitian



Lampiran 2. Linearitas Kurva Standar Pengukuran AMB berbagai Media Pengukuran





Lampiran 3. Analisis *Phase Solubility* pada berbagai konesntrasi larutan β-Siklodekstrin

Tabel 6. Analisis phase solubility (mean ± SD, n = 3)

Konsentrasi	Absorbansi	FP	Kons (mg/mL)	Rata-rata (mg)	SD	Mol	miliMol	Rata -rata (mg)	SD
	0.469	200	4.8595			5E-06	0.0053		
0 mM	0.469	200	4.8595	4.8595	0	5E-06	0.0053	0.00526	2.125E-18
	0.469	200	4.8595			5E-06	0.0053		
	0.578	200	5.9891			6E-06	0.0065		
0,5 mM	0.579	200	5.9994	5.9994	0.010363	6E-06	0.0065	0.00649	1.121E-05
	0.58	200	6.0098			7E-06	0.0065		
	0.668	200	6.9217			7E-06	0.0075		
1 mM	0.669	200	6.9321	6.9252	0.005983	8E-06	0.0075	0.00749	6.475E-06
	0.668	200	6.9217			7E-06	0.0075		
	0.786	200	8.1445			9E-06	0.0088		
1,5 mM	0.787	200	8.1549	8.1480	0.005983	9E-06	0.0088	0.00882	6.475E-06
	0.786	200	8.1445			9E-06	0.0088		
	0.892	200	9.2430			1E-05	0.0100		
2 mM	0.892	200	9.2430	9.2395	0.005983	1E-05	0.0100	0.01000	6.475E-06
	0.891	200	9.2326			1E-05	0.0100		
	1.042	200	10.7974			1E-05	0.0117		
4 mM	1.041	200	10.7870	10.8112	0.033311	1E-05	0.0117	0.01170	3.605E-05
	1.047	200	10.8492			1E-05	0.0117		
	1.135	200	11.7611			1E-05	0.0127		
6 mM	1.135	200	11.7611	11.7507	0.017949	1E-05	0.0127	0.01272	1.942E-05
	1.132	200	11.7300			1E-05	0.0127		
	1.212	200	12.5590			1E-05	0.0136		
8 mM	1.211	200	12.5487	12.5452	0.015829	1E-05	0.0136	0.01358	1.713E-05
	1.209	200	12.5279			1.36E-05	0.0136		

Lampiran 4. Analisis *Saturation solubility* dengan berbagai konsentrasi β-Siklodekstrin

Tabel 7.Analisis saturation solubility (mean ± SD, n = 3)

Formula	Replikasi	Abs	FP	Kons (mg/ml)	rata-rata (mg)	SD
AMB Murni	1	0.521	100	9.3776	9.38	0.01869
	2	0.522	100	9.3963		
	3	0.52	100	9.3589		
F1	1	0.543	180	17.6198	17.62	0.03364
	2	0.542	180	17.5862		
	3	0.544	180	17.6535		
F2	1	0.684	180	22.3637	22.35	0.05139
	2	0.682	180	22.2964		
	3	0.685	180	22.3974		
F3	1	0.702	180	22.9693	22.98	0.05139
	2	0.701	180	22.9357		
	3	0.704	180	23.0366		
F4	1	0.724	180	23.7095	23.75	0.05139
	2	0.725	180	23.7432		
	3	0.727	180	23.8105		
F5	1	0.632	200	22.9047	22.93	0.02158
	2	0.633	200	22.9421		
	3	0.633	200	22.9421		
F6	1	0.508	250	22.8364	22.85	0.02698
	2	0.508	250	22.8364		
	3	0.509	250	22.8832		
F7	1	0.506	250	22.7430	22.70	0.04673
	2	0.505	250	22.6963		
	3	0.504	250	22.6495		
F8	1	0.504	250	22.6495	22.71	0.05396
	2	0.506	250	22.7430		
	3	0.506	250	22.7430		
F9	1	0.516	250	23.2103	23.21	0.04673
	2	0.517	250	23.2570		
	3	0.515	250	23.1636		
F10	1	0.493	250	22.1355	22.10	0.05396
	2	0.493	250	22.1355		
	3	0.491	250	22.0421		

Lampiran 5. Uji Kekuatan Mekanik Formula DMN setelah Aplikasi pada Lapisan Parafilm

Tabel 8. Uji Kekuatan Mekanik Formula DMN (mean ± SD, n = 3)

Formula	Sebelum			Sesudah			Rata-Rata (% reduction)	SD
	Rep 1	Rep 2	Rep 3	Rep 1	Rep 2	Rep 3		
F1	704,12	701,22	698,56	630,41	635,66	631,18	9,8211	0,5798
F2	694,23	694,34	696,12	623,11	629,76	629,72	9,6946	0,4907
F3	699,76	703,34	698,37	642,8	640,12	642,55	8,3738	0,5374
F4	711,28	713,88	708,77	643,45	644,12	640,14	9,6638	0,1190
F5	704,24	700,12	704,82	635,12	632,33	638,52	9,6347	0,2083

Contoh perhitungan persentase penurunan tinggi needle

%reduksi tinggi *needle* = $\frac{Tinggi\ sebelum\ kompresi - tinggi\ setelah\ kompresi}{Tinggi\ sebelum\ kompresi}$ × 100%

= $\frac{704,12-630,41}{630,41} x\ 100\%$

= 9,82 %

Tabel 9. Uji Kekuatan Penetrasi di lapisan Parafilm (mean ± SD, n = 3)

Lapisan	Jumlah Lubang yang terbentuk					% Penetrasi				
	F1	F2	F3	F4	F5	F1	F2	F3	F4	F5
1	100	100	100	100	100	100	100	100	100	100
2	79	82	100	98	98	79	82	100	98	98
3	39	57	92	82	73	39	57	92	82	73
4	12	22	58	51	45	12	22	58	51	45
5	0	0	23	20	16	0	0	23	20	16
6dst	0	0	0	0	0	0	0	0	0	0

Contoh perhitungan persentasi penetrasi lapisan ke-n

Diketahui :

Jumlah lubang F3 pada lapisan ke-4 : 58

Jumlah lubang total : 100

Persamaan yang diunakan

%reduksi tinggi *needle* = $\frac{Jumlah\ lubang\ pada\ lapisan\ ke-n}{Jumlah\ lubang\ total} x\ 100\%$

= $\frac{58}{100} x\ 100$

= 58

Lampiran 6. Uji Drug Cintent Recovery

a. Hasil Penentuan Densitas

Tabel 10. Hasil Penentuan Densitas (mean ± SD, n = 3)

Formula	Ukuran Balok DMN (mm)			Volume (mm)	Berat (mg)	Densitas (mg/mm)		
	Panjang	Lebar	Tinggi			Densitas	Rata-rata	SD
F1	10	10	5.4	540	509	1.06	1.07	0.01
	10	10	5.46	546	510	1.07		
	10	10	5.44	544	509	1.07		
F2	10	10	5.54	554	521	1.06	1.05	0.01
	10	10	5.6	560	537	1.04		
	10	10	5.55	555	526	1.06		
F3	10	10	5.35	535	503	1.06	1.07	0.00
	10	10	5.38	538	502	1.07		
	10	10	5.43	543	508	1.07		
F4	10	10	5.19	519	498	1.04	1.04	0.01
	10	10	5.2	520	504	1.03		
	10	10	5.19	519	496	1.05		
F5	10	10	4.88	488	466	1.05	1.06	0.02
	10	10	4.78	478	457	1.05		
	10	10	4.87	487	451	1.08		

Contoh perhitungan volume

Diketahui

Panjang F3 = 10

Lebar F3 = 10

Tinggi F3 = 5,35

Persamaan yang digunakan :

Volume = Panjang x lebar x tinggi

Sehingga

Volume = 10 mm x 10 mm x 5,35 mm

= 535 mm^3

Contoh perhitungan densitas

Diketahui :

Volume F3 = 535 mm^3

Bobot F3 = 503 mg

Rumus yang digunakan :

$\rho = \frac{bobot}{volume}$

Sehingga

$\rho = \frac{503}{535}$

= 1,06

b. Hasil Penentuan LOD dan Persentase Jumlah Kompleks Inklusi dalam Massa Kering

Tabel 11. Hasil Penentuan LOD dan Jumlah AMB pada Mssa Kering (mean ± SD, n = 3)

Formula	B.Basah (mg)	B. Kering (mg)	LOD (%)			Jumlah AMB dalam massa kering (%)
			LOD (%)	Rata-rata	SD	
1	509	295	42.04	41.85	0.34	34.39
	509	295	42.04			
	509	298	41.45			
2	504	308	38.89	38.90	0.10	32.74
	505	309	38.81			
	505	308	39.01			
3	514	361	29.77	29.79	0.10	28.49
	515	361	29.90			
	515	362	29.71			
4	511	380	25.64	25.86	0.24	26.98
	511	379	25.83			
	513	379	26.12			
5	510	383	24.90	24.17	1.11	26.37
	510	384	24.71			
	511	394	22.90			

Contoh perhitungan LOD

Diketahui:

Bobot Basah F3 = 514

Bobot Kering F3 = 361

Persamaan yang digunakan:

% LOD $= \frac{bobot\ basah - bobot\ kering}{bobot\ basah}\ x\ 100\%$

Sehingga

$= \frac{514-361}{514} x100\%$

= 29,79 %

Contoh perhitungan persentase jumlah Kompleks Inklusi-AMB dalam massa kering

Diketahui:

Bobot KI-AMB awal = 20%

LOD = 29,79%

Persamaan yang digunakan:

%KIAMB $= \frac{bobot\ AMB}{100-LOD} x100\%$

Sehingga

%KIAMB $= \frac{20}{100-29,79\%} x100\%$

= 28,49%

c. Hasil Penentuan Volume, Bobot Jarum (*needle*), dan Bobot KI AMB

Tabel 12. Hasil Penentuan Volume dan Bobot jarum (needle) (mean ± SD, n = 3)

Formula	Bobot needle kering (mg)			Rata-rata (mg)
F1	0.99	1.00	1.00	1.00
F2	0.99	0.97	0.98	0.98
F3	0.99	1.00	1.00	1.00
F4	0.97	0.96	0.98	0.97
F5	0.98	0.98	0.98	0.98

Tabel 13.Hasil Penentuan Bobot Kompleks Inklusi-AMB (mean ± SD, n = 3)

Formula	Jumlah KI (mg)	Rata	SD
F1	0.34	0.34	0.00165
	0.34		
	0.34		
F2	0.32	0.32	0.00315
	0.32		
	0.32		
F3	0.28	0.28	0.00109
	0.28		
	0.28		
F4	0.26	0.26	0.00190
	0.26		
	0.26		
F5	0.26	0.26	0.00018
	0.26		
	0.26		

Contoh perhitungan penentuan volume, bobot jarum (*needle*), dan bobot amfoterisin B

Diketahui:

Vol satu *needle* = 0,00934 mm^3

Vol 100 *needle* = 0,00934 x 100 = 0,943 mm^3

Bobot 100 *needle* = Vol 100 *needle* x densitas F3

= 0,943 mm^3 x 1,06

= 0,9995 mg

Jumlah KI AMB dalam massa kering formula 3 (F3)

= % KI AMB bobot 100 *needle*

= 28,49 % x 0,99

= 0,28 mg

d. Hasil Penentuan Kandungan Obat

Tabel 14.Hasil Penentuan Jumlah Kompleks INklusi-AMB dalam Jarum (needle) (mean ± SD, n = 3)

Formula	KI dalam massa kering	Bobot Needle kering	Jumlah KI AMB (mg)	Rata-Rata	SD
F1	34.51	0.99	0.34	0.34	0.002
	34.51	1.00	0.34		
	34.16	1.00	0.34		
F2	32.73	0.99	0.32	0.32	0.003
	32.69	0.97	0.32		
	32.79	0.98	0.32		
F3	28.48	0.99	0.28	0.28	0.001
	28.53	1.00	0.28		
	28.45	1.00	0.28		
F4	26.89	0.97	0.26	0.26	0.002
	26.97	0.96	0.26		
	27.07	0.98	0.26		
F5	26.63	0.98	0.26	0.26	0.000
	26.56	0.98	0.26		
	25.94	0.98	0.26		

Tabel 15. Hasil Perhitungan AMB teoritis (mean ± SD, n = 3)

Formula	Jumlah AMB (mg)	Rata-rata	Jumlah AMB (µg)	Rata-rata
1	0.106	0.11	106.40	106.63
	0.107		107.37	
	0.106		106.11	
F2	0.101	0.10	101.14	100.25
	0.099		99.06	
	0.101		100.56	
F3	0.088	0.09	88.03	88.43
	0.089		88.87	
	0.088		88.39	
F4	0.081	0.08	81.46	81.55
	0.081		80.86	
	0.082		82.33	
F5	0.081	0.08	81.05	80.25
	0.081		80.84	
	0.079		78.85	

Tabel 16. Hasil Perhitungan AMB dalam 100 jarum (needle) (mean ± SD, n = 3)

Formula	Absorbansi			Konsentrasi		
	1	2	3	1	2	3
F1	0.419	0.419	0.413	21.155	21.155	20.845
F2	0.384	0.385	0.385	19.342	19.394	19.394
F3	0.349	0.349	0.348	17.528	17.528	17.477
F4	0.321	0.321	0.324	16.078	16.078	16.233
F5	0.312	0.315	0.314	15.611	15.767	15.715

Contoh perhitungan jumlah Kompleks inklusi MAB dalam *needle*

Diketahui :

KIAMB dalam massa kering F3 = 28,48

Bobot *needle* kering F3 = 0,99

Jumlah *needle* DMN = 100

Rumus yang digunakan :

Jumlah KI AMB $= \frac{KI\ dalam\ massa\ Kering}{Jumlah\ needle\ DMN} x Bobot\ needle\ kering$

Sehingga

Jumlah KI AMB $= \frac{28,48}{100} x 0,99$

= 0,28 mg

Contoh perhitungan amfoterisn b teoritis

Diketahui :

DL AMB dalam Kompleks inklusi = 31,15%

Bobot KI AMB di jarum F3 rep 1 = 0,28

Jumlah AMB dalam formula = bobot KI di *needle* x DL AMB

= 0,28 x 31,15%

= 0,088 mg

Contoh perhitungan kandungan AMB dalam 100 *needle*

Diketahui :

Persamaan kurva baku di CVB = y= 0,0107x + 0,0193

Abs F3 Rep 1 = 0,349

Kons AMB teoritis = 0,088 mg

Persamaan yang digunakan

Kons AMB $= \frac{abs-0{,}0107}{0{,}0193}$

Kons AMB $= \frac{0{,}349-0{,}0193}{0{,}0107}$

= 17,528 µg/mL

e. Hasil *Recovery*

Tabel 17. Hasil Penentuan Drug Content Recovery (mean ± SD, n = 3)

Formula	Kandungan AMB (µg)	Kandungan dalam 5 ml	% Recovery			Rata-rata	SD
			Rep 1	Rep 2	Rep 3		
F1	106.625	21.32	99.20	99.20	97.75	98.72	0.84
F2	100.253	20.05	96.47	96.73	96.73	96.64	0.15
F3	88.394	17.68	99.20	99.20	98.91	99.10	0.17
F4	81.5468	16.31	98.64	98.64	99.59	98.95	0.55
F5	80.2375	16.05	97.33	98.30	97.97	97.87	0.49

Contoh perhitungan persen *recovery*

Diketahui :

Konsentrasi AMB F3 rep 1 = 17,52

Kandungan AMB dalam 5 ml F3 = 17,68

Persamaan yang digunakan

% *Recovery* $= \frac{Kons\ AMB}{Kandungan\ AMB}\ x\ 100\%$

Sehingga

% *Recovery* $= \frac{17{,}52}{17{,}68}\ x\ 100\%$

= 99,20 %

Lampiran 7. Hasil Uji Hemolisis

Tabel 18. Hasil Uji Persen Hemolisis (mean ± SD, n = 3)

Formula	5 ppm	50 ppm	500 ppm	Formula	Hemolisis (%)		
F1	0.051	0.041	0.103	F1	0.998	1.009	0.941
F2	0.046	0.059	0.063	F2	1.003	0.989	0.985
F3	0.048	0.051	0.059	F3	1.001	0.998	0.989
F4	0.051	0.044	0.041	F4	0.998	1.006	1.009
F5	0.058	0.068	0.066	F5	0.990	0.980	0.982
IC	0.068	0.078	0.086	IC	0.980	0.969	0.960
-	0.049						
+	0.970						

Contoh perhitungan % Hemolisis

Diketahui :

Abs Kontrol Negatif = 0,049

Abs Kontrol Positif = 0,970

Abs 5 ppm F3 = 0,048

Persamaan yang digunakan :

% hemolisis $= \frac{abs\ sampel - abs\ kontrol\ negatif}{abs\ kontrol\ positif - abs\ kontrol\ negatif} X\ 100\%$

$= \frac{0{,}048 - 0{,}049}{0{,}970 - 0{,}049} X\ 100\%$

= 0,998 %

Lampiran 9. Data Statistik

a. Kelarutan Saturasi

Tests of Normality

		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	Formula	Statistic	df	Sig.	Statistic	df	Sig.
Concentration	AMB	.175	3	.	1.000	3	1.000
	F1	.175	3	.	1.000	3	1.000
	F2	.219	3	.	.987	3	.780
	F3	.269	3	.	.949	3	.567
	F4	.269	3	.	.949	3	.567
	F5	.385	3	.	.750	3	.000
	F6	.385	3	.	.750	3	.000
	F7	.196	3	.	.996	3	.878
	F8	.385	3	.	.750	3	.000
	F9	.175	3	.	1.000	3	1.000
	F10	.385	3	.	.750	3	.000

a. Lilliefors Significance Correction

Test of Homogeneity of Variances

		Levene Statistic	df1	df2	Sig.
Concentration	Based on Mean	.890	10	22	.556
	Based on Median	.217	10	22	.992
	Based on Median and with adjusted df	.217	10	12.857	.990
	Based on trimmed mean	.820	10	22	.614

ANOVA

Concentration

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	535.867	10	53.587	28430.262	.000
Within Groups	.041	22	.002		
Total	535.909	32			

b. Studi Pelepasan *In Vitro*

Tests of Normality

		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	Formula	Statistic	df	Sig.	Statistic	df	Sig.
0.25	AMB	.314	3	.	.893	3	.363
	PM	.292	3	.	.923	3	.463
	ICAMB	.175	3	.	1.000	3	1.000
1	AMB	.175	3	.	1.000	3	1.000
	PM	.253	3	.	.964	3	.637
	ICAMB	.385	3	.	.750	3	.000
2	AMB	.175	3	.	1.000	3	1.000
	PM	.219	3	.	.987	3	.780
	ICAMB	.314	3	.	.893	3	.363
3	AMB	.385	3	.	.750	3	.000
	PM	.385	3	.	.750	3	.000
	ICAMB	.219	3	.	.987	3	.780
4	AMB	.385	3	.	.750	3	.000
	PM	.385	3	.	.750	3	.000
	ICAMB	.204	3	.	.993	3	.843
5	AMB	.385	3	.	.750	3	.000
	PM	.253	3	.	.964	3	.637
	ICAMB	.219	3	.	.987	3	.780
6	AMB	.385	3	.	.750	3	.000
	PM	.253	3	.	.964	3	.637
	ICAMB	.328	3	.	.871	3	.298
7	AMB	.385	3	.	.750	3	.000
	PM	.175	3	.	1.000	3	1.000
	ICAMB	.328	3	.	.871	3	.298
8	AMB	.175	3	.	1.000	3	1.000
	PM	.175	3	.	1.000	3	1.000
	ICAMB	.343	3	.	.842	3	.220
18	AMB	.385	3	.	.750	3	.000
	PM	.385	3	.	.750	3	.000
	ICAMB	.292	3	.	.923	3	.463
24	AMB	.385	3	.	.750	3	.000
	PM	.292	3	.	.923	3	.463
	ICAMB	.175	3	.	1.000	3	1.000

a. Lilliefors Significance Correction

Test of Homogeneity of Variances

		Levene Statistic	df1	df2	Sig.
0.25	Based on Mean	2.036	2	6	.211
	Based on Median	.333	2	6	.729
	Based on Median and with adjusted df	.333	2	4.028	.735
	Based on trimmed mean	1.824	2	6	.241
1	Based on Mean	.903	2	6	.454
	Based on Median	.077	2	6	.927
	Based on Median and with adjusted df	.077	2	3.714	.927
	Based on trimmed mean	.789	2	6	.496
2	Based on Mean	1.570	2	6	.283
	Based on Median	.429	2	6	.670
	Based on Median and with adjusted df	.429	2	4.027	.678
	Based on trimmed mean	1.461	2	6	.304
3	Based on Mean	2.333	2	6	.178
	Based on Median	1.083	2	6	.397
	Based on Median and with adjusted df	1.083	2	4.364	.415
	Based on trimmed mean	2.241	2	6	.188
4	Based on Mean	3.484	2	6	.099
	Based on Median	2.400	2	6	.171
	Based on Median and with adjusted df	2.400	2	2.632	.255
	Based on trimmed mean	3.421	2	6	.102
5	Based on Mean	1.895	2	6	.230
	Based on Median	1.091	2	6	.394
	Based on Median and with adjusted df	1.091	2	4.102	.417
	Based on trimmed mean	1.840	2	6	.238
6	Based on Mean	3.185	2	6	.114
	Based on Median	.464	2	6	.649
	Based on Median and with adjusted df	.464	2	3.365	.664
	Based on trimmed mean	2.782	2	6	.140
7	Based on Mean	4.560	2	6	.062
	Based on Median	.615	2	6	.571
	Based on Median and with adjusted df	.615	2	2.952	.598
	Based on trimmed mean	3.975	2	6	.080
8	Based on Mean	7.111	2	6	.026
	Based on Median	.800	2	6	.492
	Based on Median and with adjusted df	.800	2	2.188	.549
	Based on trimmed mean	6.125	2	6	.036
18	Based on Mean	2.897	2	6	.132
	Based on Median	.412	2	6	.680
	Based on Median and with adjusted df	.412	2	4.412	.686
	Based on trimmed mean	2.509	2	6	.161
24	Based on Mean	2.897	2	6	.132
	Based on Median	.778	2	6	.501
	Based on Median and with adjusted df	.778	2	3.176	.531
	Based on trimmed mean	2.681	2	6	.147

ANOVA

		Sum of Squares	df	Mean Square	F	Sig.
0.25	Between Groups	123.005	2	61.503	1712.797	.000
	Within Groups	.215	6	.036		
	Total	123.221	8			
1	Between Groups	170.183	2	85.091	4614.684	.000
	Within Groups	.111	6	.018		
	Total	170.293	8			
2	Between Groups	433.629	2	216.815	5195.535	.000
	Within Groups	.250	6	.042		
	Total	433.880	8			
3	Between Groups	592.426	2	296.213	12717.542	.000
	Within Groups	.140	6	.023		
	Total	592.566	8			
4	Between Groups	698.803	2	349.402	9231.462	.000
	Within Groups	.227	6	.038		
	Total	699.030	8			
5	Between Groups	820.778	2	410.389	15661.815	.000
	Within Groups	.157	6	.026		
	Total	820.935	8			
6	Between Groups	983.797	2	491.898	12068.024	.000
	Within Groups	.245	6	.041		
	Total	984.041	8			
7	Between Groups	1253.584	2	626.792	16996.132	.000
	Within Groups	.221	6	.037		
	Total	1253.806	8			
8	Between Groups	1346.004	2	673.002	11007.429	.000
	Within Groups	.367	6	.061		
	Total	1346.371	8			
18	Between Groups	3785.520	2	1892.760	84796.477	.000
	Within Groups	.134	6	.022		
	Total	3785.654	8			
24	Between Groups	4288.621	2	2144.311	129971.709	.000
	Within Groups	.099	6	.016		
	Total	4288.720	8			

c. Kemampuan Mekanik DMN

Tests of Normality

		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	Formula	Statistic	df	Sig.	Statistic	df	Sig.
% High Reduction	F1	.285	3	.	.932	3	.495
	F2	.291	3	.	.924	3	.468
	F3	.335	3	.	.858	3	.262
	F4	.231	3	.	.980	3	.731
	F5	.258	3	.	.960	3	.616

a. Lilliefors Significance Correction

Test of Homogeneity of Variances

		Levene Statistic	df1	df2	Sig.
% High Reduction	Based on Mean	2.614	4	10	.099
	Based on Median	.481	4	10	.749
	Based on Median and with adjusted df	.481	4	6.343	.750
	Based on trimmed mean	2.342	4	10	.125

ANOVA

% High Reduction

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	4.303	4	1.076	5.827	.011
Within Groups	1.846	10	.185		
Total	6.149	14			

d. *Drug Recovery Content*

Tests of Normality

		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	Formula	Statistic	df	Sig.	Statistic	df	Sig.
Drug Recovery	F1	.385	3	.	.750	3	.000
	F1	.385	3	.	.750	3	.000
	F1	.385	3	.	.750	3	.000
	F2	.385	3	.	.750	3	.000
	F2	.253	3	.	.964	3	.637

a. Lilliefors Significance Correction

Test of Homogeneity of Variances

		Levene Statistic	df1	df2	Sig.
Drug Recovery	Based on Mean	4.388	4	10	.026
	Based on Median	.370	4	10	.825
	Based on Median and with adjusted df	.370	4	4.493	.821
	Based on trimmed mean	3.626	4	10	.045

ANOVA

Drug Recovery

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	12.529	4	3.132	11.990	.001
Within Groups	2.612	10	.261		
Total	15.141	14			

e. *Surface pH*

Tests of Normality

		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	Formula	Statistic	df	Sig.	Statistic	df	Sig.
Surface pH	F1	.208	3	.	.992	3	.826
	F1	.353	3	.	.824	3	.174
	F1	.217	3	.	.988	3	.792
	F2	.187	3	.	.998	3	.915
	F2	.338	3	.	.852	3	.246

a. Lilliefors Significance Correction

Test of Homogeneity of Variances

		Levene Statistic	df1	df2	Sig.
Surface pH	Based on Mean	1.366	4	10	.313
	Based on Median	.423	4	10	.789
	Based on Median and with adjusted df	.423	4	5.484	.788
	Based on trimmed mean	1.279	4	10	.341

ANOVA

Surface pH

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	.198	4	.049	2.432	.116
Within Groups	.203	10	.020		
Total	.401	14			

f. *Water Vapor Transmission Rate*

Tests of Normality

		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	Formula	Statistic	df	Sig.	Statistic	df	Sig.
Water Vapour Transmission Rate	F1	.361	3	.	.807	3	.132
	F1	.252	3	.	.965	3	.640
	F1	.298	3	.	.915	3	.435
	F2	.221	3	.	.986	3	.772
	F2	.264	3	.	.954	3	.587

a. Lilliefors Significance Correction

Test of Homogeneity of Variances

		Levene Statistic	df1	df2	Sig.
Water Vapour Transmission Rate	Based on Mean	.372	4	10	.824
	Based on Median	.128	4	10	.969
	Based on Median and with adjusted df	.128	4	9.075	.968
	Based on trimmed mean	.347	4	10	.840

ANOVA

Water Vapour Transmission Rate

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	.022	4	.006	2.555	.104
Within Groups	.022	10	.002		
Total	.044	14			